IP Library Granted Patent US 11,261,501
Granted Patent B2
US 11,261,501 · App. 16/683,897 · Granted Mar 1, 2022

Detection method for Neisseria gonorrhoeae

Inventors: Danny Filer (Bristol, GB); Claire Ferrao (Trowbridge, GB); Sharon Chadwick (Trowbridge, GB)
Assignee: Binx Health Limited
C12Q1/689C12Q2600/158C12Q2600/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,261,501
App. No.
16/683,897
Granted
Mar 1, 2022
Kind
B2
Abstract

A method of detecting the presence of Neisseria gonorrhoeae in a sample. The method involves detecting a first target sequence taken from the NGO1642 gene and/or a second target sequence taken from the NGO1012 gene. The method may involve a step of amplifying the target sequence, and may involve hybridising the target sequence to a nucleic acid probe and identifying hybridisation. The method may involve simultaneous detection of other target sequences, e.g. from other pathogens.

Claims (13)

1. A method of detecting Neisseria gonorrhoeae in a sample, said method comprising:

amplifying a sequence within SEQ ID NO: 1 using a pair of primers that produces an amplicon comprising a target sequence therein, wherein said target sequence comprises 23 to 140 contiguous nucleotides within SEQ ID NO: 1; and

wherein said primer pair comprises a forward primer comprising 18 to 22 contiguous nucleotides within SEQ ID NO: 4 and a reverse primer comprising 19 to 26 contiguous nucleotides within SEQ ID NO: 5;

hybridizing said target sequence to a labelled probe complimentary to said target sequence to determine a presence of said target sequence.

2. The method of claim 1 , further comprising identifying a state of said labelled probe, wherein said state determines an occurrence of hybridization.

3. The method of claim 1 , further comprising detecting for a presence of Chlamydia trachomatis or Trichomonas vaginalis.

4. The method of claim 1 , wherein the probe comprises a sequence comprising 5 contiguous nucleotides within SEQ ID No: 3.

5. The method of claim 1 , wherein one or both primers comprise modified nucleotides.

6. The method of claim 5 , wherein the modified nucleotides comprise phosphorothioate linkages.

7. The method of claim 1 , wherein one or more of the primers and probe comprise locked nucleic acids.

8. The method of claim 1 , wherein the probe comprises an electrochemical label.

9. The method of claim 8 , wherein the electrochemical label is a metal-carbocyclic label.

10. The method of claim 9 , wherein the electrochemical label is a ferrocene label.

Assignments (6)
SECURITY INTEREST Recorded Mar 25, 2025
From: BINX HEALTH LIMITED
To: KREOS CAPITAL VII (UK) LIMITED
Reel/Frame 070620/0287 →
RELEASE OF SECURITY INTEREST Recorded Jan 18, 2025
From: BX HEP AGGREGATOR, LLC,
To: BINX HEALTH LIMITED
Reel/Frame 069925/0466 →
ASSIGNMENT OF PATENT SECURITY AGREEMENT Recorded Oct 3, 2024
From: ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP
To: BX HEP AGGREGATOR, LLC
Reel/Frame 069107/0116 →
PATENT SECURITY AGREEMENT Recorded Apr 7, 2021
From: BINX HEALTH LIMITED
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP
Reel/Frame 055859/0724 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2020
From: FERRAO, CLAIRE; FILER, DANNY; CHADWICK, SHARON
To: ATLAS GENETICS LIMITED
Reel/Frame 051739/0937 →
CHANGE OF NAME Recorded Dec 12, 2019
From: ATLAS GENETICS LIMITED
To: BINX HEALTH LIMITED
Reel/Frame 051264/0447 →
Priority Claims (1)
GB 1416459 · Sep 17, 2014 · national
Continuity (2)
Continuation 15511893
Related Publication 20200140930A1 · May 7, 2020